Experimental Treatment for Gastrointestinal Inflammation
common.study.values.description
“Radiation Dose in Humans From Orally Administered Tc99m-Heparin”
This is a research study of a new agent used for evaluation of inflammation in the GI tract. This agent is investigational and thus is being studied to determine appropriate dosing and administration in both normal controls (i.e. people without gastrointestinal complaints) and patients with eosinophilic disease (i.e. those with an immune reaction and inflammation in their bodies with a certain cell called an eosinophil). The study will test whether the radiolabeled agent will bind to the inflammation of eosinophilic esophagitis patients because an animal model of eosinophilic esophagitis which shows the striking deposition of eosinophil granule proteins is not available.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Radiation - Computerized Tomography scan
imaging scan from a person's eyes to their thighs
Radiation - Single Photon Emission Computed Tomography scans
imaging scan taken during, and after, the administration of the radioactive agent
Drug - Technetium Tc 99M
subjects are administered radioactive heparin as part of study participation.
Radiation - Planar Images
2 dimensional imaging - whole body planar scans
Procedure - Esophagogastroduodenoscopy
esophagogastroduodenoscopy with tissue biopsies
participant.views.study.view.additional
participant.views.study.view.scientific-title
Radiation Dose in Humans From Orally Administered Tc99m-Heparin
common.study.values.clinical-trial-id
NCT04069429
participant.views.study.view.id
b2kBNd
